Vivek Reddy
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vivek Reddy sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Vivek Reddy: 20 sponsored US clinical trials, 3 recruiting.
Vivek Reddy sponsors 20 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Persistent Atrial Fibrillation, with 3 trials.
Top-decile sponsor footprint
Vivek Reddy ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (64.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
REPRESENT-PF Registry
NCT07535268
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
NCT06765356
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
NCT05988411
LS-PersAFone: Pulsed Field Ablation for Long-Standing Persistent Atrial Fibrillation
NCT06128174
Versatility of a Circular Multielectrode Catheter in the Individualized Recognition & Treatment of Atrial Fibrillation and Related Arrhythmias Using Pulsed Field Energy
NCT06056557
Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation
NCT04182620
Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)
NCT04358029
Model Based Fast Anatomical Mapping
NCT03349476
ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization
NCT03370536
Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias
NCT03204981
RADAR Clinical Trial
NCT03263702
REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients
NCT01747837
REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation
NCT01858194
Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation
NCT01635998
The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise
NCT01619800
Deviating the Esophagus in Atrial Fibrillation Ablation
NCT01546168
Impact of Renal SympAthetic DenerVation on Chronic HypErtension
NCT01628198
Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia
NCT01546207
Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
NCT01294267
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
NCT01014741
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Vivek Reddy enrollment is open (later-stage tilt)
3 recruiting of 20 indexed (15% open); 11 completed (55%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Persistent Atrial Fibrillation (3 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vivek Reddy: open-pipeline peers nationwide
Peers matched on 20 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Vivek Reddy sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Hoag Memorial Hospital Presbyterian · 15% recruiting · 20 trials
- Medtronic Neurovascular Clinical Affairs · 15% recruiting · 20 trials
- Georgetown University · 15% recruiting · 227 trials
- Arizona State University · 15% recruiting · 187 trials
Related
What to do with this Vivek Reddy page
20 registered trials is a research-attention snapshot, not an endorsement of Vivek Reddy or any single study.
- 3 of Vivek Reddy's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Persistent Atrial Fibrillation is the condition Vivek Reddy studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Persistent Atrial Fibrillation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vivek Reddy pipeline card: 20 registered trials from official public datasets.Report a data error.